Metaxalone

Source: Wikipedia, the free encyclopedia.
Not to be confused with Metolazone, a diuretic.
Metaxalone
Clinical data
Trade namesSkelaxin
AHFS/Drugs.comMonograph
MedlinePlusa682010
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
BioavailabilityUnknown
MetabolismLiver
Elimination half-life9.2 ± 4.8 hours
ExcretionKidney
Identifiers
  • 5-[(3,5-dimethylphenoxy)methyl]-1,3-oxazolidin-2-one
JSmol)
  • O=C2OC(COc1cc(cc(c1)C)C)CN2
  • InChI=1S/C12H15NO3/c1-8-3-9(2)5-10(4-8)15-7-11-6-13-12(14)16-11/h3-5,11H,6-7H2,1-2H3,(H,13,14) checkY
  • Key:IMWZZHHPURKASS-UHFFFAOYSA-N checkY
  (verify)

Metaxalone, sold under the brand name Skelaxin, is a muscle relaxant medication used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions.[1] Its exact mechanism of action is not known, but it may be due to general central nervous system depression.[1] It is a moderately strong muscle relaxant, with relatively low incidence of side effects.[citation needed]

Common side effects include nausea, vomiting, drowsiness, and central nervous system (CNS) side effects, such as dizziness, headache, and irritability.[1]

The metabolism of metaxalone involves enzymes CYP1A2 and CYP2C19 in the cytochrome P450 system. [medical citation needed] Because many medications are metabolized by enzymes in this system, precaution must be taken when administering it with other medications involving the P450 system to avoid interactions.[2]

Because of the potential for side effects, this drug is considered high risk in the elderly.[medical citation needed]

Pharmacokinetics

Metaxalone exhibits increased bioavailability when taken with food.[3] Specifically, in one study, compared to fasted conditions, the presence of food at the time of drug administration increased Cmax by 77.5%, AUC0-t by 23.5%, and AUC0-∞ by 15.4%.[4] Metaxalone is a substrate of CYP1A2 and CYP2C19, an inhibitor of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A, and an inducer of CYP1A2 and CYP3A4.[2]

Assay

A literature survey reveals very few methods are reported for the determination of metaxalone to date. Nirogi et al.[4] reported a liquid chromatographic method coupled to tandem mass spectrometry for the quantification of metaxalone in human plasma. A stability-indicating HPLC method was introduced by P.K. Sahu et al.[5] Metaxalone has been used as an internal standard for few analytical methods.[6][7]

References

  1. ^ a b c d "Skelaxin- metaxalone tablet". DailyMed. U.S. National Library of Medicine. 27 April 2018. Retrieved 23 October 2020.
  2. ^ a b US 7378434, Du J, Roberts RH, "Metaxalone products, method of manufacture, and method of use", issued 27 May 2008, assigned to Takeda Pharmaceuticals USA Inc. 
  3. ^ "Skelaxin Package Insert". King Pharmaceuticals, Inc. Archived from the original on 9 March 2010.
  4. ^
    PMID 16803662
    .
  5. doi:10.1155/2011/645710
    .
  6. PMID 17481969
    .
  7. PMID 18313371
    .

External links

  • "Metaxalone". Drug Information Portal. U.S. National Library of Medicine.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Metaxalone&oldid=1190949375"